Tesamorelin

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the production and release of growth hormone. It’s FDA-approved for HIV-associated lipodystrophy and raises GH and IGF-1 levels. Research shows it supports lean tissue and mass, making it effective for both fat loss and muscle building.

Mechanism of Action

Tesamorelin works by binding to GHRH receptors in the pituitary gland, stimulating the release of growth hormone. This leads to increased lipolysis (fat breakdown), particularly targeting visceral adipose tissue, while also promoting lean muscle development through elevated GH and IGF-1.

Benefits

• •FDA-approved for HIV-associated lipodystrophy
• •Significant reduction in visceral fat
• •Supports lean tissue and muscle mass development
• •Better studied than most peptides
• •Targets dangerous belly fat specifically
• •May improve overall body composition

Side Effects & Negatives

• •Water retention and bloating
• •Joint pain and muscle aches
• •Changes in blood sugar levels
• •Injection site reactions
• •Sharply raises IGF-1 levels
• •Potential glucose intolerance

Safety Profile

FDA-approved but still carries real risks. The sharp increase in IGF-1 has been linked to tumor growth in some studies. Better studied than most alternatives but requires careful monitoring due to potential serious adverse effects.

Dosage Information

FDA-approved dose: 2mg subcutaneous injection daily. Clinical trials used this standard dosing. Should only be used under medical supervision due to safety concerns.

Research Studies

• 1. Falutz et al. (2010): Phase 3 trial showing 15% reduction in visceral fat in HIV patients over 26 weeks
• 2. Stanley et al. (2014): Demonstrated sustained visceral fat reduction and improved liver fat in HIV patients with lipodystrophy
• 3. Grinspoon et al. (2010): FDA approval study showing efficacy in reducing visceral fat but highlighting glucose intolerance risks